AbbVie Inc. Debt/Assets

Debt/Assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending December 30, 2019 was 74.88% (a 15.9% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Assets increased by 14.44%
  • Annual Debt/Assets for 2019 was 74.88% (a 10.25% increase from previous year)
  • Annual Debt/Assets for 2018 was 67.92% (a 28.66% increase from previous year)
  • Annual Debt/Assets for 2017 was 52.79% (a -5.29% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of AbbVie Inc.

Most recent Debt/Assetsof ABBV including historical data for past 10 years.

Interactive Chart of Debt/Assets of AbbVie Inc.

AbbVie Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 74.88% 64.61% 65.21% 65.43% 74.88%
2018 67.92% 61.22% 60.2% 53.77% 67.92%
2017 52.79% 54.9% 55.58% 56.27% 52.79%
2016 55.74% 56.0% 56.31% 59.41% 55.74%
2015 59.7% 58.59% 57.79% 57.2% 59.7%
2014 54.44% 51.99% 50.75% 50.27% 54.44%
2013 50.42% 52.42% 52.88% 55.35% 50.42%
2012 58.03% 0.0% 0.0% 0.0% 58.03%
2011 0.25% 0.0% 0.0% 0.0% 0.25%
2010 0.0% 0.0%
2009 0.0% 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.